Eptinezumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain), DMC (Denmark) and HAS (France), among others, recommended or restricted eptinezumab, while AOTMIT (Poland) and NYE METODER (Norway) did not recommend it.
The record spans 3.1 years, opening at AWMSG (Wales) on 7 Jan 2022 and running to 26 Feb 2025.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
The file is active: 6 of 12 records date from 2023 or later.
3 distinct indication wordings are recorded for eptinezumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 12 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess eptinezumab, on 7 Jan 2022; AOTMIT (Poland) did not open a file until 26 Feb 2025 — a wide spread of 3.1 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 6 of 12 dated records fall in 2022 alone.
Restriction is doing real work here: 3 of 10 decisive outcomes narrowed eptinezumab to a subgroup rather than accepting or refusing it outright, at NICE (England), SMC (Scotland) and TLV (Sweden).
eptinezumab has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for eptinezumab reads 5 recommended, 3 restricted, 2 not recommended and 1 no benefit, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| AOTMIT (Poland) | 26 Feb 2025 | programu lekowego B.133 „Profilaktyczne leczenie chorych na migrenę przewlekłą (ICD- 10: G43) | not recommended | source |
| ZIN (Netherlands) | 28 Jul 2023 | Pakketadvies sluisgeneesmiddel eptinezumab (Vyepti®) voor de behandeling van migraine | reimbursed (sluis) | source |
| NYE METODER (Norway) | 21 May 2023 | Profylakse mot migrene hos voksne som har minst 4 migrenedager per måned. | not introduced | source |
| NICE (England) | 1 Mar 2023 | NICE TA871 | recommended (optimised) | source |
| G-BA (Germany) | 16 Feb 2023 | Vyepti — benefit assessment §35a | added benefit: not proven | source |
7 further decisions for eptinezumab, across 7 agencies, are not shown here. They link to 7 further source documents.
Related molecules
- galcanezumab — same ATC class N02C — Analgesics
- erenumab — same ATC class N02C — Analgesics
- fremanezumab — same ATC class N02C — Analgesics
- atogepant — same ATC class N02C — Analgesics
- rimegepant — same ATC class N02C — Analgesics
- sumatriptan — same ATC class N02C — Analgesics
Coverage: 12 decisions for eptinezumab from 12 agencies, 2022 to 2025. Data to 7 Sep 2026. ATC class N02C — Analgesics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.